According to the earnings report the company posted on Monday after market close, that's a 20% sequential and 166% year-over-year pop in revenue. GAAP diluted earnings per share were negative $0.01.
Cantor Fitzgerald's Pablo Zuanic kept an 'Overweight' rating on Curaleaf stock, lowering the price target to $24 from $26.50.
The analyst said Tuesday that the reported sequential organic sales growth of 18% was "above the underlying market growth of low teens in the company's markets."
According to Zuanic, sales from the company's top five states, including Florida, …